USAMMDA WEMT Development Partners Visit Critical Innovations

Critical Innovations hosts USAMMDA WEMT development partners at its Los Angeles facility.

Critical Innovations hosted visitors from the U.S. Army Medical Materiel Development Activity (USAMMDA) Warfighter Expeditionary Medicine and Treatment (WEMT) Program Management Office at its Los Angeles facility in July. During the visit, the WEMT team reviewed the progress of two technologies currently under development by Critical Innovations in two separate product areas:

• Noncompressible Hemorrhage Control (NHC)

• Burn Treatment and Skin Repair (BTSR)

USAMMDA’s WEMT Project Management Office leads the development and fielding of FDA-cleared or approved medical devices, drugs and biologics that fulfill unmet requirements identified by the U.S. Department of Defense end users.

No official endorsement of third parties or their products is made or inferred.

Critical Innovations’ President & CEO, Dr. Ross Donaldson, describes the company’s on-site prototyping and manufacturing capabilities to USAMMDA WEMT visitors.